168 related articles for article (PubMed ID: 30272587)
1. Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia.
Song MM; Makena MR; Hindle A; Koneru B; Nguyen TH; Verlekar DU; Cho H; Maurer BJ; Kang MH; Reynolds CP
Anticancer Drugs; 2019 Feb; 30(2):117-127. PubMed ID: 30272587
[TBL] [Abstract][Full Text] [Related]
2. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
[TBL] [Abstract][Full Text] [Related]
3. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators.
Batra S; Reynolds CP; Maurer BJ
Cancer Res; 2004 Aug; 64(15):5415-24. PubMed ID: 15289350
[TBL] [Abstract][Full Text] [Related]
4. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines.
Maurer BJ; Metelitsa LS; Seeger RC; Cabot MC; Reynolds CP
J Natl Cancer Inst; 1999 Jul; 91(13):1138-46. PubMed ID: 10393722
[TBL] [Abstract][Full Text] [Related]
5. Reactive Oxygen Species Mediates the Synergistic Activity of Fenretinide Combined with the Microtubule Inhibitor ABT-751 against Multidrug-Resistant Recurrent Neuroblastoma Xenografts.
Chen NE; Maldonado NV; Khankaldyyan V; Shimada H; Song MM; Maurer BJ; Reynolds CP
Mol Cancer Ther; 2016 Nov; 15(11):2653-2664. PubMed ID: 27530131
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines.
Makena MR; Cho HE; Nguyen TH; Koneru B; Verlekar DU; Hindle A; Kang MH; Reynolds CP
Pediatr Blood Cancer; 2018 Dec; 65(12):e27447. PubMed ID: 30251395
[TBL] [Abstract][Full Text] [Related]
8. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism.
Maurer BJ; Melton L; Billups C; Cabot MC; Reynolds CP
J Natl Cancer Inst; 2000 Dec; 92(23):1897-909. PubMed ID: 11106681
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-mediated fenretinide (4-HPR) resistance in childhood acute lymphoblastic leukemia cells.
Yang B; Fan L; Fang L; He Q
Cancer Chemother Pharmacol; 2006 Oct; 58(4):540-6. PubMed ID: 16520989
[TBL] [Abstract][Full Text] [Related]
10. P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models.
Lopez-Barcons L; Maurer BJ; Kang MH; Reynolds CP
Int J Cancer; 2017 Jul; 141(2):405-413. PubMed ID: 28340497
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.
Poliakov E; Samuel W; Duncan T; Gutierrez DB; Mata NL; Redmond TM
PLoS One; 2017; 12(4):e0176487. PubMed ID: 28448568
[TBL] [Abstract][Full Text] [Related]
12. Fenretinide-induced caspase-8 activation and apoptosis in an established model of metastatic neuroblastoma.
Raguénez G; Mühlethaler-Mottet A; Meier R; Duros C; Bénard J; Gross N
BMC Cancer; 2009 Mar; 9():97. PubMed ID: 19331667
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids.
Cuperus R; Tytgat GA; Leen R; Brites P; Bras J; Caron HN; Van Kuilenburg AB
Int J Oncol; 2008 May; 32(5):1011-9. PubMed ID: 18425327
[TBL] [Abstract][Full Text] [Related]
14. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.
Cooper JP; Reynolds CP; Cho H; Kang MH
Exp Biol Med (Maywood); 2017 Jun; 242(11):1178-1184. PubMed ID: 28429653
[TBL] [Abstract][Full Text] [Related]
15. 4-oxo-N-(4-hydroxyphenyl)retinamide: two independent ways to kill cancer cells.
Tiberio P; Cavadini E; Abolafio G; Formelli F; Appierto V
PLoS One; 2010 Oct; 5(10):e13362. PubMed ID: 20976277
[TBL] [Abstract][Full Text] [Related]
16. Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex.
Maurer BJ; Kalous O; Yesair DW; Wu X; Janeba J; Maldonado V; Khankaldyyan V; Frgala T; Sun BC; McKee RT; Burgess SW; Shaw WA; Reynolds CP
Clin Cancer Res; 2007 May; 13(10):3079-86. PubMed ID: 17505011
[TBL] [Abstract][Full Text] [Related]
17. p75 neurotrophin receptor and fenretinide-induced signaling in neuroblastoma.
Ganeshan VR; Schor NF
Cancer Chemother Pharmacol; 2014 Feb; 73(2):271-9. PubMed ID: 24253178
[TBL] [Abstract][Full Text] [Related]
18. Fenretinide (4-HPR) Targets Caspase-9, ERK 1/2 and the Wnt3a/β-Catenin Pathway in Medulloblastoma Cells and Medulloblastoma Cell Spheroids.
Bassani B; Bartolini D; Pagani A; Principi E; Zollo M; Noonan DM; Albini A; Bruno A
PLoS One; 2016; 11(7):e0154111. PubMed ID: 27367907
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation.
Ponzoni M; Bocca P; Chiesa V; Decensi A; Pistoia V; Raffaghello L; Rozzo C; Montaldo PG
Cancer Res; 1995 Feb; 55(4):853-61. PubMed ID: 7850799
[TBL] [Abstract][Full Text] [Related]
20. N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).
Faderl S; Lotan R; Kantarjian HM; Harris D; Van Q; Estrov Z
Leuk Res; 2003 Mar; 27(3):259-66. PubMed ID: 12537979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
